Evidence map›Paper›PMID 41439032›Full record

ArticleBiotechnology reports (Amsterdam, Netherlands)2026

Indole-alkaloid-rich fraction of

Chirantan Majumder, Anirban Manna, Satyajit Halder, Somesh Roy, Subhash C Mandal, Kuladip Jana, Mahadeb Pal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biotechnology reports (Amsterdam, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chirantan MajumderDivision of Molecular Medicine, Bose Institute, Kolkata, India.
Anirban MannaDivision of Molecular Medicine, Bose Institute, Kolkata, India.
Satyajit HalderDivision of Molecular Medicine, Bose Institute, Kolkata, India.
Somesh RoyDivision of Molecular Medicine, Bose Institute, Kolkata, India.
Subhash C MandalDepartment of Pharmaceutical Technology, Jadavpur University, Kolkata, India.
Kuladip JanaDivision of Molecular Medicine, Bose Institute, Kolkata, India.
Mahadeb PalDivision of Molecular Medicine, Bose Institute, Kolkata, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current anti-breast cancer therapies often cause severe toxicity to normal cells and promote chemoresistance, while their exorbitant costs limit their accessibility to many patients. This underscores the need for safer, effective, and affordable alternative treatment strategies. In this study, we evaluated the anti-breast cancer potential of an alkaloid-rich dichloromethane fraction of

Indexed as

4T1-allograftBreast cancerErvatamia coronariaIndole-alkaloidsMitochondrial membrane potential (MMP)Reactive oxygen species (ROS)

Identifiers

PMID41439032
PMCPMC12720107

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.